GlassScriptPhysician profile
Fawad Virk
NPI 1396150165
$12,059.74
in general payments reported to CMS, 2019-2025
31 companies · $4,136 in 2025
The $4,136 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,971 · 2020: $1,905 · 2021: $507 · 2022: $1,070 · 2023: $1,120 · 2024: $1,350 · 2025: $4,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Travel and Lodging: $2,095 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,490.88 |
| Travel and Lodging | $2,095.30 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,457.77 | 2019-2025 | General - Therapies, General - Vascular Intervention, Ekosonic |
| Medtronic, INC. | $1,714.47 | 2021-2025 | Micra, Onyx Frontier, Symplicity G3 |
| Abiomed | $1,220.73 | 2020-2025 | Impella |
| Philips North America LLC | $1,075.54 | 2022-2025 | Igt Devices Undivided, Eagle Eye |
| Biotronik INC. | $695.05 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $684.34 | 2020-2025 | Lifevest |
| Abbott Laboratories | $637.61 | 2019-2024 | Jot Dx |
| Novartis Pharmaceuticals Corporation | $586.96 | 2021-2025 | |
| Amgen INC. | $545.14 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $372.31 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.49 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $263.07 | 2019-2022 | |
| Edwards Lifesciences Corporation | $222.32 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $206.67 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $203.02 | 2019-2025 | Camzyos, Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $140.24 | 2020 | |
| Nuwellis, INC. | $100.97 | 2019 | |
| Pfizer INC. | $99.37 | 2019-2025 | |
| Shockwave Medical, INC | $96.71 | 2022 | |
| Angiodynamics, INC. | $80.49 | 2020-2024 | Auryon Laser System 100-120 Vac |
| Chiesi USA, INC. | $75.13 | 2021 | |
| Novo Nordisk INC | $66.04 | 2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $38.68 | 2021-2025 | |
| Cvrx, INC. | $32.65 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $32.09 | 2022 | |
| Esperion Therapeutics, INC. | $30.20 | 2022-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $24.27 | 2024 | |
| Amarin Pharma, INC. | $24.13 | 2021-2022 | |
| Daiichi Sankyo INC. | $16.14 | 2024 | Injectafer |
| Terumo Medical Corporation | $13.77 | 2024 | Angio-Seal |
| Teleflex LLC | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawad Virk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.